Why prevention is finally winning
For most of modern medicine, cardiovascular disease has been treated reactively — after the heart attack, after the stroke, after the diagnosis. New genomic screening panels are changing that.
What the data shows
A 2024 longitudinal study of 18,000 adults found that polygenic risk scores predicted major cardiovascular events with 89% accuracy a full decade before traditional markers raised alarms.
- Combined with lipid panels and ApoB testing, accuracy exceeded 95%.
- High-risk patients who began statins at age 40 saw a 43% reduction in events.
- Lifestyle interventions alone reduced events by 22%.
What this means for you
If you have a family history of heart disease, ask your clinician about genomic risk screening. Insurance coverage is expanding rapidly.
Prevention is no longer about waiting — it's about reading the signal early.
